Download A Phase II Study of the PARP Inhibitor, Iniparib (BSI-201), in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Vered Stearns, M.D.
Associate Professor of Oncology
Co-Director, Breast Cancer Program
Breast Cancer Research Chair in Oncology
Breast Cancer Program
1650 Orleans Street
CRB I, Room 144
Baltimore, MD 21231-1000
Phone: 443-287-6489
Fax: 410-614-4073
E-mail: [email protected]
RE: A Phase II Study of the PARP Inhibitor, Iniparib (BSI-201), in Combination with
Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis (NA_00036553, SKCCC
J1081, TBCRC 018)
Dear Fellow Physician,
It is our pleasure to send a brief update of our phase II research study evaluating the efficacy of Iniparib
(BSI-201, Sanofi-Aventis/BiPAR Sciences), plus irinotecan chemotherapy to treat women with
progressive triple negative breast cancer brain metastases.
Below are some high points:
•
Eligibility includes two groups: (1) patients with progressive brain metastases after radiation
therapy, or (2) patients who are radiation therapy-naive and asymptomatic.
•
Treatment includes irinotecan on days 1 and 8 of a 21 day cycle, with iniparib on days 1, 4, 8 and
11. All study-based therapy will be administered intravenously.
•
Monitoring for intracranial and extracranial response will occur every 9 weeks with a brain MRI
and a CT of chest/abdomen and pelvis.
This trial is being open through the Translational Breast Cancer Research Consortium and includes
several sites across the country. Please see more information here:
http://clinicaltrials.gov/ct2/show/NCT01173497?term=iniparib+and+irinotecan&rank=2
We would welcome referrals of your patients with triple negative breast cancer brain metastases. For
more information or to discuss eligibility questions, please email [email protected].
Sincerely,
Vered Stearns, M.D.
Principal Investigator: Vered Stearns, M.D.
Protocol Number: NA_00036553
Approved December 20, 2011